Spruce Biosciences, Inc. SPRB
42.76 USD -1.79 (-4.02%)
Nov 3, 2026, 3:24 PM EST
42.76 Day range 45.27
38.06 52-week range 129.00
- YTD
- -50.91%
- 1 year
- -59.18%
Analyst view
Consensus: hold
Hold
Price target (mean) 1.83 -95.7% downside
Now 42.76
- Target (low)
- 1.00
- Target (mean)
- 1.83
- Target (high)
- 3.00
Ratings (0m) 5 0 buy · 5 hold · 0 sell
- Strong buy0
- Buy0
- Hold5
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 5
- 2 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.205 | -0.25 – -0.16 | -0.23 | +10.9% | 885.00K | -69.3% | 4 |
| Next quarter | -0.19667 | -0.22 – -0.17 | -0.28 | +29.8% | 500.00K | -75.0% | 3 |
| Current year | -0.93 | -0.99 – -0.87 | -1.24 | +25.0% | 5.09M | -49.5% | 4 |
| Next year | -0.6375 | -0.92 – -0.27 | -0.93 | +31.4% | 1.60M | -68.6% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 16, 2024 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Dec 12, 2024 | Guggenheim | Reiterated | Neutral | Neutral |
| Dec 11, 2024 | JMP Securities | Downgrade | Market Outperform | Market Perform |
| Dec 11, 2024 | RBC Capital | Reiterated | Sector Perform | Sector Perform |
| Dec 11, 2024 | Oppenheimer | Downgrade | Outperform | Perform |
| Nov 12, 2024 | RBC Capital | Reiterated | Sector Perform | Sector Perform |
| Aug 19, 2024 | HC Wainwright & Co. | Reiterated | — | Neutral |
| Aug 13, 2024 | RBC Capital | Reiterated | Sector Perform | Sector Perform |
| Jun 13, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Jun 5, 2024 | HC Wainwright & Co. | Reiterated | — | Neutral |
| May 14, 2024 | HC Wainwright & Co. | Reiterated | — | Neutral |
| Mar 14, 2024 | RBC Capital | Downgrade | Outperform | Sector Perform |
| Mar 14, 2024 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Mar 14, 2024 | Leerink Partners | Downgrade | Outperform | Market Perform |
| Mar 14, 2024 | JMP Securities | Maintained | Market Outperform | Market Outperform |
| Mar 14, 2024 | Ladenburg Thalmann | Downgrade | Buy | Neutral |
| Mar 14, 2024 | Guggenheim | Downgrade | Buy | Neutral |
| Mar 5, 2024 | RBC Capital | Reiterated | Outperform | Outperform |
| Feb 26, 2024 | RBC Capital | Maintained | Outperform | Outperform |
| Feb 21, 2024 | Guggenheim | Initiated | — | Buy |
| Nov 20, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 13, 2023 | RBC Capital | Reiterated | Outperform | Outperform |
| Sep 13, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 8, 2023 | SVB Leerink | Upgrade | Market Perform | Outperform |
| Aug 18, 2023 | Oppenheimer | Maintained | Outperform | Outperform |
| Aug 18, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 16, 2023 | JMP Securities | Maintained | Outperform | Outperform |
| Aug 15, 2023 | RBC Capital | Reiterated | Outperform | Outperform |
| Jun 13, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 23, 2023 | Oppenheimer | Reiterated | Outperform | Outperform |